Medical Policy. MP Specialty Drugs. Related Policies Guidelines for Prior Authorization of Pharmacologic Therapies
|
|
- Cecily Gregory
- 5 years ago
- Views:
Transcription
1 Medical Policy Last Review: 04/30/2018 Effective Date: 07/01/2018 Section: Prescription Drug Related Policies Guidelines for Prior Authorization of Pharmacologic Therapies DISCLAIMER Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. POLICY Drug-Specific Prior Authorization Criteria All coverage requests will be reviewed according to the criteria in the Specialty Drug Table. The drug specific criteria will be applied to the specialty drugs listed in the Specialty Drug Table located in Table 1. in the Appendix below. POLICY GUIDELINES are injectable and non-injectable medications that are typically used to treat complex conditions and meet one or more of the following criteria: are biotech-derived or biological in nature; are significantly higher cost than traditional medications; are used in complex treatment regimens; require special delivery, storage and handling; require special medication-administration training for patients; require on-going monitoring of medication adherence, side effects, and dosage changes; are available through limited-distribution channels; and may require additional support and coordinated case management o all medications on the Blue Cross of Idaho (BCI) prior authorization list must go through the prior authorization process. For a list of medications that require a prior authorization, click here o FDA indication alone does not establish the medical necessity of a particular medication for a particular patient. We may review all coverage requests for medical necessity and in accordance with the terms of the member s contract. Criteria Utilized Appropriate clinical documentation must be provided in order to review requests for coverage. Medication requests will be reviewed according to established criteria. Criteria and resources used in coverage determinations may include but not limited to: Eligibility for coverage according to the terms of the member contract
2 Medical necessity/investigational criteria according to the member contract The Food and Drug Administration (FDA) Blue Cross Blue Shield Association Center for Clinical Effectiveness (CCE ) (formerly Technology Evaluation Center [TEC] assessments) The Blue Cross and Blue Shield Association Medical Policy Reference Manual as adopted by BCI Blue Cross of Idaho Medical Policies McKesson/Change Health InterQual Criteria Criteria established by a designated pharmacy benefits manager such as the Clinical Authorization System (CAS) as adopted from CVS/Caremark The National Comprehensive Cancer Network (see Oncologic Drug Use below) NovoLogix Specialty Guidance Management Criteria Facts & Comparisons Compendium The American Hospital Formulary Service Drug Information Compendium Current published medical literature and peer review publications based upon scientific evidence Evidence-based guidelines developed by national organizations and recognized authorities Other criteria as adopted by the Blue Cross of Idaho Medical Policy Committee or Pharmacy and Therapeutics Committee All requested therapies, supplies and services will be evaluated in accordance with the following criteria: Medically Necessary the Covered Services or supplies required to identify or treat an Insured s condition, Disease, Illness or Accidental Injury and which, as recommended by the treating Physician or other Covered Provider and as determined by Blue Cross of Idaho, are: The most appropriate supply or level of service, considering potential benefits and harms to the Insured. Proven to be effective in improving health outcomes; o For new treatments, effectiveness is determined by scientific evidence; o For existing treatments, effectiveness is determined first by scientific evidence, then by professional standards, then by expert opinion. Not primarily for the convenience of the Insured or Covered Provider. Cost-effective for this condition, compared to alternative treatments, including no treatment. Cost-effectiveness does not necessarily mean lowest price. Investigational any technology (service, supply, procedure, treatment, drug, device, facility, equipment or biological product), which is in a developmental stage or has not been proven to improve health outcomes such as length of life, quality of life, and functional ability. A technology is considered investigational if, as determined by Blue Cross of Idaho, it fails to meet any one of the following criteria: The technology must have final approval from the appropriate government regulatory body. This applies to drugs, biological products, devices, and other products/procedures that must have approval from the U.S. Food and Drug Administration (FDA) or another federal authority before they can be marketed. Interim approval is not sufficient. The condition for which the technology is approved must be the same as that BCI is evaluating. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes. The evidence should consist of current published medical literature and investigations published in peer-reviewed journals. The quality of the studies and consistency of results will be considered. The evidence should demonstrate that the technology can measure or alter physiological changes related to a Disease, injury, Illness, or condition. In Original Policy Date: April 2018 Page: 2
3 addition, there should be evidence that such measurement or alteration affects health outcomes. The technology must improve the net health outcome. The technology s beneficial effects on health outcomes should outweigh any harmful effects on health outcomes. The technology must be as beneficial as any established alternatives. The technology must show improvement that is attainable outside the investigational setting. Improvements must be demonstrated when used under the usual conditions of medical practice. These definitions may not apply to some health plans, such as Federal Employee Program (FEP), Medicare Advantage and some self-funded group plans. Blue Cross of Idaho reserves the right to periodically update its definitions. For more specific information on Formulary Exception Requests, Oncologic Drug Use, and Off-Label Drug Use, please see MP REFERENCES 1. Amgen Manufacturing Limited. Nplate (romiplastin) prescribing information. Thousand Oaks CA: Amgen Manufacturing Limited; Available from: [cited Apr ]. 2. Black, Dennis M., et al. "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis." New England Journal of Medicine (2007): Institute for Clinical Systems Improvement (ISCI). Diagnosis and treatment of osteoporosis Available from: [cited Jan ]. 4. Lo, Ernest, and Sean Deane. "Diagnosis and classification of immune-mediated thrombocytopenia." Autoimmunity reviews 13.4 (2014): Lyles, Kenneth W., et al. "Zoledronic acid and clinical fractures and mortality after hip fracture." New England Journal of Medicine (2007): Martins, Ana Maria, et al. "Recommendations on diagnosis, treatment, and monitoring for Gaucher disease." The Journal of pediatrics (2009): S10-S National Institute of Health. Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease Available from: [cited Nov ]. 8. Neunert, Cindy, et al. "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia." Blood (2011): Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) prescribing information. East Hanover NJ: Novartis Pharmaceutics Corporation; Available from: [cited Jan ]. Original Policy Date: April 2018 Page: 3
4 CODES 10. Pastores and Hughes. Gaucher Disease Available from: ncbi.nlm.nih.gov/books/nbk1269/ [cited Jul ]. 11. Pfizer Labs. Elelyso (Taliglucerase alfa) prescribing information. New York NY; Pfizer Labs; Available form: [cited Nov ]. 12. Provan, Drew, et al. "International consensus report on the investigation and management of primary immune thrombocytopenia." Blood (2010): Räkel, Agnès, Andrée Boucher, and Louis-Georges Ste-Marie. "Role of zoledronic acid in the prevention and treatment of osteoporosis." Clinical interventions in aging 6 (2010): Reid, David M., et al. "Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid- induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial." The Lancet (2009): Shire Human Genetic Therapies, Inc. VPRIV (velaglucerase) prescribing information. Lexington MA: Shire Human Genetic Therapies, Inc.; Available from: PI Prescribing Information [cited Nov ]. 16. US Preventive Services Task Force. "Screening for osteoporosis in postmenopausal women: recommendations and rationale." Annals of Internal Medicine (2002): World Health Organization Scientific Group. Assessment of osteoporosis at the primary care level. Technical Report Available from: [cited Jan ]. 18. Zeng, Yan, et al. "TPO receptor agonist for chronic idiopathic thrombocytopenic purpura." Cochrane Database Syst Rev 7 (2011). 19. Zimran et al. Pivotal trial with plant-cell expressed recombinant glucocerebrosidase, Taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood (22). Available from: [cited Nov ]. Codes Number Description HCPCS J2796 Injection, romiplostim, Nplate, 10 mcg J3060 Injection, taliglucerase alfa, Elelyso, 10 units J3385 Injection, velaglucerase alfa, VPRIV, 100 units J3489 Injection, zoledronic acid, Reclast, 1 mg Original Policy Date: April 2018 Page: 4
5 POLICY HISTORY Date Action Reason 06/15/16 Added to Prescription Drug section New policy to address DMARD and biologic specialty drugs. 06/22/17 Replace policy Blue Cross of Idaho annual update; no changes to policy statement. 07/26/17 Replace policy Added Cost Effective DMARD alternatives to policy guidelines, effective 10/01/ /28/17 Replace policy Added cost effective Alpha 1-Proteinase Inhibitors and Gaucher Disease Agents alternatives to policy guidelines, effective 12/01/ /27/17 Replace policy Added cost-effectiveness language for Gaucher s Disease Agents and MAB therapy for MS; Effective 03/15/ /30/18 Replace policy Removed cost effectiveness language for: DMARD alternatives, Alpha 1-Proteinase Inhibitors, MAB therapy for MS, and Gaucher Disease Agents. Removed the following specialty drugs from the specialty drug table: Abatacept, Alpha 1- Proteinase Inhibitors, Denosumab, Golimumab, Natalizumab, Tocilizumab, and Vedolizumab. References 1-2, 4-8, 10-20, 22-24, 27, 29-32, 38, 40, 42, 44-46, 48-55, and Remaining references renumbered in references and Specialty Drug table. Policy renumbered from to Changes to policy will become effective 07/01/2018. Original Policy Date: April 2018 Page: 5
6 APPENDIX Table 1. Drug Name Medically Necessary (if all the following criteria apply): Contraindications/ Exclusions: Step Therapy Required: Additional Required Clinical Criteria: References: Romiplostin (Nplate) Immune Thrombocytopenia (ITP) 1. Confirmed by a specialist 2. Maintenance therapy for platelet count < 30 x10 (9)/L 3. Over age 18 Bleeding episode (urgent) Prior therapy with: Corticosteroid and/or immune globulin with treatment failure, due to one of the following: 1. Significant intolerance 2. Continued platelet count < 30 x10 (9)/L 3. Allergic response Risk of thrombosis discussed with patient or caregiver 1, 4, 8, 12, 18 Taliglucerase alfa (Elelyso) Type 1 Gaucher disease (confirmed by Betaglucosylceramidase activity or GBA gene test) Age 18 and 65 Type 2 Gaucher Disease Type 3 Gaucher disease With one of the following: 1. Anemia 2. Thrombocytopenia 3. Splenomegaly 4. Hepatomegaly 5. Bone disease 7, 10, 11, 18 Original Policy Date: April 2018 Page: 6
7 Velaglucerase Alfa (VPRIV) Type 1 Gaucher disease (confirmed by Betaglucosylceramidase activity or GBA gene test) Age 18 and 65 Type 2 Gaucher Disease Type 3 Gaucher disease With one of the following: 1. Anemia 2. Thrombocytopenia 3. Splenomegaly 4. Hepatomegaly 5. Bone disease 6, 10, 15, 19 Zoledronic Acid (Reclast) Osteoporosis or Osteopenia treatment in post-menopausal women Osteoporosis in men Paget s Disease 1. With consistent radiographic findings 2. Elevated serum alkaline phosphatase Glucocorticoid-induced osteoporosis (GIO) or treatment with glucocorticoids for more than 3 months Current treatment with similar medication (e.g., Zometa, Xgeva, or Prolia) Pregnancy Under 18 years of age Treatment with zoledronic acid within the past year Hypocalcemia Tried and/or failed oral bisphosphonates Patients with creatinine clearance of 35mL/min and in those with evidence of acute renal impairment Osteopenic (T-score -1.0 to -2.5) or osteoporotic (T-score below -2.5) by dual x-ray absorptiometry (DXA), or low impact fracture Renal function evaluated and no evidence of renal impairment Normal phosphorus and magnesium levels Planned supplementation with calcium and Vitamin-D Osteoporosis treatment (postmenopausal females, males) and GIO treatment: 5 mg once a year Osteoporosis prevention (postmenopausal women) treatment: 5 mg once every two years Paget s disease treatment: a single 5 mg infusion 2, 3, 5, 9, 13, 14, 16, 17 Original Policy Date: April 2018 Page: 7
Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD
Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):
More informationMP Specialty Drugs: Drug-Specific Criteria
Abatacept (Orencia) J0129 Moderate to Severe Active Adult RA 1. Rheumatologist confirmed Not to be used in combination with another biologic DMARD Prior treatment with nonbiologic Disease- Modifying Antirheumatic
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (VPRIV) Reference Number: CP.PHAR.163 Effective Date: 02.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.241 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationPROLIA: Medical Coverage Policy Denosumab (Prolia and. Xgeva) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Denosumab (Prolia and Xgeva) EFFECTIVE DATE: 11 01 2016 POLICY LAST UPDATED: 12 19 2017 OVERVIEW Prolia (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationParathyroid Hormone Analogs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.36 Subject: Parathyroid Hormone Analogs Page: 1 of 6 Last Review Date: September 15, 2017 Parathyroid
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationFYI ONLY Generic Name. Generics available. zoledronic acid N/A
Criteria Document: Reference #: PC/A011 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Promacta) Reference Number: CP.PHAR.180 Effective Date: 03.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationTREATMENTS FOR GAUCHER DISEASE
TREATMENTS FOR GAUCHER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: denosumab_prolia_xgeva 3/2011 9/2017 9/2018 9/2017 Description of Procedure or Service Receptor activator
More informationPrior Authorization Required: Yes as shown below
PROLIA, XGEVA (denosumab) MB9409 Covered Service: Prior Authorization Required: Additional Information Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes as shown below Must be
More informationTYMLOS (abaloparatide)
TYMLOS (abaloparatide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationClinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:
Clinical Policy: (Promacta) Reference Number: ERX.SPA.71 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Substrate Reduction Therapy Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Substrate Reduction Therapy! Prime Therapeutics will review Prior Authorization
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cerezyme) Reference Number: CP.PHAR.154 Effective Date: 02.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationCorporate Medical Policy Investigational (Experimental) Services
Corporate Medical Policy Investigational (Experimental) Services File Name: Origination: investigational_(experimental)_services 1/1996 Description of Procedure or Service BCBSNC defines the terms "investigational"
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationPromacta (eltrombopag)
Promacta (eltrombopag) Policy Number: 5.01.542 Last Review: 5/2018 Origination: 6/2013 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Promacta
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection
Pharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection Table of Contents Policy: Commercial Policy History References Coding Information Information Pertaining to All Policies
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03.01.11 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/A011 Page 1 of 8 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 15, 2017 Promacta Description Promacta
More informationXgeva. Xgeva (denosumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.18 Subject: Xgeva Page: 1 of 5 Last Review Date: March 16, 2018 Xgeva Description Xgeva (denosumab)
More informationTreatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)
Prescribing Clinical Network Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) Crawley and Horsham & Mid-Sussex CCG Treatment pathway for adult
More informationPharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)
Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Policy: Denosumab (Prolia, Xgeva) Reference Number: CP.PHAR.58
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03/11 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 20, 2018 Promacta Description Promacta
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Forteo) Reference Number: CP.PHAR.188 Effective Date: 11.15.17 Last Review Date: 02.19 Line of Business: Commercial* (Exchange Plans), HIM, Medicaid Coding Implications Revision Log See
More informationClinical Policy: Abaloparatide (Tymlos) Reference Number: CP.CPA.306 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Tymlos) Reference Number: CP.CPA.306 Effective Date: 06.13 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationXgeva. Xgeva (denosumab) Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.18 Subject: Xgeva Page: 1 of 5 Last Review Date: December 3, 2015 Xgeva Description Xgeva (denosumab)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03.01.11 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Actonel, Atelvia) Reference Number: CP.PMN.100 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Reclast, Zometa) Reference Number: CP.PHAR.59 Effective Date: 03.11 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationProlia 2 shots a year proven to help strengthen bones. next shot appointment
Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com next shot appointment For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationBisphosphonate Step Therapy Criteria
ϯ ϯ ϯ A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association Bisphosphonate Step Therapy Criteria Program may
More informationReclast Doctor Discussion Guide
For more information about Reclast, visit www.reclast.com Reclast Doctor Discussion Guide Whether you re a newly diagnosed patient or you re currently receiving treatment for osteoporosis, our Reclast
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationThe 2017 CMS Merit-based Incentive Payment System includes 2 inflammatory bowel disease (IBD) measures.
The 2017 CMS Merit-based Incentive Payment System includes 2 inflammatory bowel disease (IBD) measures. Measure Specifications for Registry Reporting MIPS #271: Inflammatory Bowel Disease (IBD): Preventive
More informationFORTEO (teriparatide) INJECTION
FORTEO (teriparatide) INJECTION Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationRETIRED. Maximum Drug Dose Policy
RETIRED DRUG POLICY Policy Number 2017D0034A Maximum Drug Dose Policy Annual Approval Date 3/1/2017 Approved By UnitedHealthcare National Pharmacy & Therapeutics Committee United Healthcare Community Plan
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.51 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy for
More informationMedication Policy Manual. Topic: Prolia, denosumab Date of Origin: August 11, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru223 Topic: Prolia, denosumab Date of Origin: August 11, 2010 Committee Approval Date: August 11,
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationACTEMRA (tocilizumab)
ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationvedolizumab (Entyvio )
vedolizumab (Entyvio ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),
More informationProlia 2 shots a year proven to help strengthen bones.
For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven to help strengthen bones. Blythe Danner, Award winning actress taking Prolia. Prolia is
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Natpara (parathyroid hormone) Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Natpara (parathyroid hormone) Prime Therapeutics will review Prior Authorization
More informationName of Policy: Therapeutic Apheresis, with Extracorporeal Column Immunoadsorption and Plasma Reinfusion
Name of Policy: Therapeutic Apheresis, with Extracorporeal Column Immunoadsorption and Plasma Reinfusion Policy #: 010 Latest Review Date: December 2008 Category: Surgical Policy Grade: Effective March
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationburosumab (Crysvita )
burosumab (Crysvita ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationMedication Prior Authorization Form
Reclast (Zoledronic Acid) Policy Number: 1050 Policy History Approve Date: 12/11/2015 Revise Dates: 8/22/2016 Next Review: 12/11/2016 Review Dates: Preauthorization All Plans Benefit plans vary in coverage
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationSAVAYSA (edoxaban tosylate) oral tablet
SAVAYSA (edoxaban tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Cerdelga, Zavesca Reference Number: CP.CPA.240 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationand will be denied as not medically necessary** if not met. This criterion only applies to the initial
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationScottish Medicines Consortium
Scottish Medicines Consortium eltrombopag, 25mg and 50mg film-coated tablets (Revolade ) No. (625/10) GlaxoSmithKline UK 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Indacaterol/Glycopyrrolate (Utibron Neohaler) Reference Number: CP.PMN.147 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationCarelirst.+.V Family of health care plans
Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (DDAVP Injection, Stimate) Reference Number: CP.PHAR.214 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Coding Implications Revision
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cerdelga) Reference Number: CP.PHAR.153 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: No Coverage Criteria/Off-Label Use Policy Reference Number: CP.PMN.53 Effective Date: 07.01.18 Last Review Date: 05.01.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More informationName of Policy: Computer-aided Detection (CAD) Mammography
Name of Policy: Computer-aided Detection (CAD) Mammography Policy #: 112 Latest Review Date: October 2010 Category: Radiology Policy Grade: Active Policy but no longer scheduled for regular literature
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationdichlorphenamide (Keveyis )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationGuidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
More information[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationAdministration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More information